The Global Health Body Sounds Warning Over Severe Shortage of Weight-Loss Jabs
Fewer than 10% of people eligible to benefit from GLP-1 drugs such as Wegovy are able to get them, states the World Health Organization as it publishes its inaugural guidance on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging increased and just access to GLP-1 medication.
According to projections, over two billion could be obese by 2030 if no action is taken.
"The new guidelines acknowledges that obesity is a lifelong illness that can be managed with comprehensive and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are significant barriers to widespread access to the treatments that can aid individuals in losing considerable body mass, says the body.
GLP-1 Therapy Shortage
Even in the current most optimistic case, the supply of GLP-1 therapies might only reach approximately 100 million people – less than 10% of those who need them, according to the health organization.
The recommendation urges nations and manufacturers to widen availability, through strategies like licensing agreements.
The intellectual property rights on a key compound – the core component of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.
How Obesity Drugs Function
The injections mimick a biological compound to delay gastric emptying, reduce hunger and boost the sense of being full so individuals consume fewer calories.
Patients usually start to lose weight after several weeks of commencing the once-weekly jabs.
Research indicates patients may regain a significant portion within a year of halting the drug, when their typical hunger resume.
To be overweight or obese raises your chance for developing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight impacts individuals in every country and was associated with 3.7 million fatalities worldwide in 2024, according to the WHO.
